Measurable residual disease (MRD) is defined as the persistence of a small number of malignant cells post-treatment, which are not detected through conventional methods, and can lead to relapse or contribute to disease progression. The use of MRD status as a prognostic indicator has become increasingly prominent in the field of hematologic malignancies, with its role in response assessment and treatment decision-making being evaluated in a number of clinical trials. For example, several ongoing studies are exploring the use of MRD assays in determining whether treatment can be de-escalated or withdrawn if MRD is undetectable.
MRD can be detected from peripheral blood or bone marrow aspirates using a range of methods, all of which have different benefits and limitations, including multiparametric flow cytometry (MFC) and reverse-transcriptase quantitative PCR (RT-qPCR), with high throughput techniques being implemented in the context of next-generation flow cytometry (NGF) and next-generation sequencing (NGS). Whilst significant advances have been made in the understanding of MRD, its implications and its development for clinical application, further exploration and validation of MRD assessment methods and monitoring strategies is required in order to enable and optimize its use as a surrogate endpoint in clinical practice.
The aim of this collection is to collate studies advancing and investigating the use and application of MRD in the management of patients with hematologic malignancies. This collection will accept manuscripts on, but not limited to, the following research areas:
● Advances in the use of existing tools and techniques for MRD detection and monitoring
● Novel tools and techniques for MRD detection and monitoring
● The correlation between MRD status and disease progression
● MRD relapse
● Clinical trials incorporating MRD status
● The application of MRD in clinical practice
● The potential future uses of MRD
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Measurable residual disease (MRD) is defined as the persistence of a small number of malignant cells post-treatment, which are not detected through conventional methods, and can lead to relapse or contribute to disease progression. The use of MRD status as a prognostic indicator has become increasingly prominent in the field of hematologic malignancies, with its role in response assessment and treatment decision-making being evaluated in a number of clinical trials. For example, several ongoing studies are exploring the use of MRD assays in determining whether treatment can be de-escalated or withdrawn if MRD is undetectable.
MRD can be detected from peripheral blood or bone marrow aspirates using a range of methods, all of which have different benefits and limitations, including multiparametric flow cytometry (MFC) and reverse-transcriptase quantitative PCR (RT-qPCR), with high throughput techniques being implemented in the context of next-generation flow cytometry (NGF) and next-generation sequencing (NGS). Whilst significant advances have been made in the understanding of MRD, its implications and its development for clinical application, further exploration and validation of MRD assessment methods and monitoring strategies is required in order to enable and optimize its use as a surrogate endpoint in clinical practice.
The aim of this collection is to collate studies advancing and investigating the use and application of MRD in the management of patients with hematologic malignancies. This collection will accept manuscripts on, but not limited to, the following research areas:
● Advances in the use of existing tools and techniques for MRD detection and monitoring
● Novel tools and techniques for MRD detection and monitoring
● The correlation between MRD status and disease progression
● MRD relapse
● Clinical trials incorporating MRD status
● The application of MRD in clinical practice
● The potential future uses of MRD
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.